N@N

JO, NNA, TBNK, OMER, CVE, CDXS Are Seasonally Ripe To Go Down In the Next Five Weeks

^{Published on 2017-04-21 01:45:25 - WOPRAI}
 

April 21, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net is monitoring the Seasonality of iPath Dow Jones-AIG Coffee Total Return Sub-IndexSM ETN (NYSE:JO), Navios Maritime Acquisition Corporation (NYSE:NNA), Territorial Bancorp Inc. (NASDAQ:TBNK), Omeros Corporation (NASDAQ:OMER), Cenovus Energy Inc. (NYSE:CVE), Codexis, Inc. (NASDAQ:CDXS) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. buyins.net is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

The following stocks are expected to go Down:

  Symbol  Company                          Expected Return  Odds                 By The Following Date
  JO      iPath Dow Jones-AIG Coffee Total Return Sub-IndexSM ETN  -2.56%           87.50% (7 of 8)      Monday, April 24th 2017
  NNA     Navios Maritime Acquisition Corporation  -1.83%           100.00% (8 of 8)     Monday, May 1st 2017
  TBNK    Territorial Bancorp Inc.         -2.04%           85.71% (6 of 7)      Friday, May 19th 2017
  OMER    Omeros Corporation               -2.75%           100.00% (7 of 7)     Monday, April 24th 2017
  CVE     Cenovus Energy Inc.              -7.41%           85.71% (6 of 7)      Friday, May 12th 2017
  CDXS    Codexis, Inc.                    -9.36%           85.71% (6 of 7)      Friday, May 5th 2017

Navios Maritime Acquisition Corporation (NYSE:NNA) - Navios Maritime Acquisition Corporation provides marine transportation services worldwide. It owns a fleet of crude oil, refined petroleum product, and chemical tankers. The company charters its vessels to oil companies, refiners, and large vessel operators under long, medium, and short term charters. As of April 4, 2017, its fleet consisted of a total of 36 double-hulled tanker vessels aggregating approximately 3.9 million deadweight tons, which included 8 VLCC tankers, 8 Long Range 1 product tankers, 18 Medium Range 2 product tankers, and 2 chemical tankers. The company was founded in 2008 and is based in Monaco..

Territorial Bancorp Inc. (NASDAQ:TBNK) - Territorial Bancorp Inc. operates as the bank holding company for Territorial Savings Bank that provides various financial services to individuals, families, and businesses in Hawaii. The company offers a range of deposit accounts, including passbook and statement savings accounts, certificates of deposit, money market accounts, commercial and regular checking accounts, and NOW accounts. It also provides various loan products comprising one- to four-family residential mortgage loans; home equity loans and lines of credit; construction, commercial, and other non-residential real estate loans; consumer loans; multi-family mortgage loans; commercial business loans; and other loans, as well as offers investment securities. In addition, the company, through its subsidiary, Territorial Financial Services, Inc. engages in insurance agency activities. Further, it provides various non-deposit investments, including annuities and mutual funds through a third-party broker-dealer. Territorial Bancorp Inc. offers its products and services through approximately 28 full-service branch offices. The company was founded in 1921 and is headquartered in Honolulu, Hawaii..

Omeros Corporation (NASDAQ:OMER) - Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use during cataract surgery or intraocular lens replacement. Its clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases. The company s clinical programs also consists of OMS824, which is in Phase II clinical trial for the treatment of Huntington's diseases and schizophrenia; OMS405 that is in Phase II clinical trial to treat opioid and nicotine addiction; and OMS201, which is in Phase I/II clinical trial for use during urological procedures. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; OMS721 for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and OMS616 to control surgical and traumatic bleeding. The company s preclinical programs also include GPR17 for the treatment of myelin formation; GPR101 for appetite and eating disorders; GPR151 to treat schizophrenia and cognition; GPR161 for triple-negative breast cancer treatment; GPR183 for the treatment of osteoporosis, and Epstein-Barr virus infections and related diseases; GPR174 for modulation of the immune system; and Antibody Platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. In addition, the company is developing OMS103 that has completed Phase III clinical trial for arthroscopic anterior cruciate ligament reconstruction and arthroscopic partial meniscectomy. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington..

Cenovus Energy Inc. (NYSE:CVE) - Cenovus Energy Inc. develops, produces, and markets crude oil, natural gas liquids (NGLs), and natural gas in Canada. Its Oil Sands segment develops and produces bitumen assets at Foster Creek, Christina Lake, Narrows Lake, and the Athabasca natural gas assets, as well as projects in the early stages of development, such as Grand Rapids and Telephone Lake. The company s Conventional segment engages in the development and production of conventional crude oil, NGLs, and natural gas in Alberta and Saskatchewan in Canada, including the heavy oil assets at Pelican Lake. This segment also includes the carbon dioxide enhanced oil recovery project at Weyburn. Its Refining and Marketing segment transports, sells, and refines crude oil into petroleum and chemical products. This segment also owns 50% interest ownership in two refineries in the United States. The company is headquartered in Calgary, Canada..

Codexis, Inc. (NASDAQ:CDXS) - Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company s platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also improves the pharmaceuticals companies manufacturing productivity and efficiency, as well as helps in outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. Further, the company develops biocatalysts for use in the fine chemicals market, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California..

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net